BioSpace News Archive

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) and Syntimmune have just today announced that Alexion will be acquiring Syntimmune, a company working to produce antibody therapeutics that focus on the neonatal Fc receptor (FcRn).

Karolinska Development’s portfolio company Asarina Pharma will today be listed on Nasdaq First North in Stockholm.

Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other serious diseases, announced the formation of its inaugural Scientific Advisory Board.

Oculis, announces the appointment of Pravin U. Dugel, M.D. as Chairman of its Scientific Advisory Board (SAB). Dr. Dugel is internationally recognized for his research in the field of ophthalmologic diseases and brings extensive clinical experience.

Horizon Discovery Group plc, announced the launch of its Myeloid DNA Reference Standard. The first-to-market large cell-line derived myeloid cancer reference standard designed enables faster, more reliable and more cost-effective assay validation, to support the market in bringing routine testing into practice.

Kavya Kopparaputo be Named a 2018 Davidson Fellow

GENFIT today announces some key leadership changes to accompany GENFIT into the next stage of its development and its evolution from an R&D biotechnology company to a fully-integrated biopharmaceutical company.

GlaxoSmithKline (GSK) and the non-profit Aeras reported that their M72/AS01E vaccine candidate significantly cut the rate of pulmonary tuberculosis in HIV-negative adults with latent tuberculosis infection.

Merck and Co., like many large corporations, has a mandatory retirement age of 65 for its chief executive officer. Today the company announced its board of directors and rescinded the policy to allow its current chief executive officer, Kenneth C. Frazier, stay on beyond his 65th birthday in December 2019.

The past few days has had a flurry of activity in the industry with leadership changes. Let’s take a look at some of those!